BRAF Biomarkers
News and reporting on BRAF biomarkers.
Braftovi, Mektovi Approved in Europe for BRAF V600E-Mutant NSCLC
A Phase II trial of the combo demonstrated response rates of 75 percent and 46 percent in treatment-naïve and previously treated NSCLC patients, respectively.
Lung Cancer Groups Seek Public Comment on Updated Biomarker Testing Guidelines
Updated guidelines recommend certain biomarker tests for early- and late-stage lung cancer at the time of diagnosis.
Ipsen Licenses Day One's Ojemda Outside US in Deal Worth $461M
Ojemda was approved in the US earlier this year as a treatment for BRAF-altered pediatric low-grade glioma.
The firm expects to share positive data for a protein degrader targeting BRAF alterations later in 2024 after a setback early this year.
NICE Recommends Novartis' BRAF, MEK Inhibitor Combo for BRAF-Mutant Pediatric Glioma
The UK's National Institute for Health and Care Excellence recommended the combination treatment for pediatric patients with BRAF V600E-mutant low- or high-grade glioma.